Helen Sheldon

3.6k total citations · 1 hit paper
32 papers, 2.4k citations indexed

About

Helen Sheldon is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Helen Sheldon has authored 32 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 13 papers in Cancer Research and 5 papers in Oncology. Recurrent topics in Helen Sheldon's work include Angiogenesis and VEGF in Cancer (8 papers), Cancer, Hypoxia, and Metabolism (7 papers) and MicroRNA in disease regulation (5 papers). Helen Sheldon is often cited by papers focused on Angiogenesis and VEGF in Cancer (8 papers), Cancer, Hypoxia, and Metabolism (7 papers) and MicroRNA in disease regulation (5 papers). Helen Sheldon collaborates with scholars based in United Kingdom, United States and Greece. Helen Sheldon's co-authors include Adrian L. Harris, Francesca M. Buffa, Jiannis Ragoussis, Christos Sotiriou, John Moore, Jonathan Gleadle, Stefano Colella, Carme Camps, Russell Leek and Richard C.A. Sainson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, SHILAP Revista de lepidopterología and The EMBO Journal.

In The Last Decade

Helen Sheldon

32 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

hsa-miR-210 Is Induced by Hypoxia and Is an Independent Prognostic Factor in Breast Cancer

2008 540 citations Carme Camps, Francesca M. Buffa et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Helen Sheldon United Kingdom	19	1.9k	1.4k	329	241	185	32	2.4k
Yi‐Mi Wu United States	10	1.9k 1.0×	1.2k 0.8×	361 1.1×	209 0.9×	297 1.6×	44	2.5k
Riccardo Sgarra Italy	24	1.5k 0.8×	754 0.5×	280 0.9×	144 0.6×	129 0.7×	62	1.9k
Nabendu Pore United States	17	1.4k 0.7×	1.1k 0.8×	614 1.9×	244 1.0×	287 1.6×	26	2.3k
Nijiro Nohata Japan	39	3.1k 1.6×	2.6k 1.9×	393 1.2×	211 0.9×	312 1.7×	62	3.7k
Lian‐Yue Yang China	31	1.7k 0.9×	1.1k 0.8×	424 1.3×	160 0.7×	236 1.3×	57	2.4k
Scott M. Welford United States	24	1.6k 0.8×	1.2k 0.8×	418 1.3×	278 1.2×	671 3.6×	60	2.6k
Yohko Nakamura Japan	30	1.7k 0.9×	702 0.5×	537 1.6×	235 1.0×	137 0.7×	86	2.4k
Danfang Zhang China	30	1.7k 0.9×	1.1k 0.8×	861 2.6×	280 1.2×	282 1.5×	65	2.4k
Aaron N. Chang United States	20	2.1k 1.1×	1.4k 1.0×	273 0.8×	503 2.1×	137 0.7×	34	3.0k
Zhengsheng Wu China	27	1.5k 0.8×	953 0.7×	683 2.1×	201 0.8×	185 1.0×	69	2.3k

Countries citing papers authored by Helen Sheldon

Since Specialization

Citations

This map shows the geographic impact of Helen Sheldon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helen Sheldon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helen Sheldon more than expected).

Fields of papers citing papers by Helen Sheldon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helen Sheldon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helen Sheldon. The network helps show where Helen Sheldon may publish in the future.

Co-authorship network of co-authors of Helen Sheldon

This figure shows the co-authorship network connecting the top 25 collaborators of Helen Sheldon. A scholar is included among the top collaborators of Helen Sheldon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helen Sheldon. Helen Sheldon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Heer, Ellen C. de, Christos E. Zois, Edward G. Bridges, et al.. (2023). Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer. Journal of Experimental & Clinical Cancer Research. 42(1). 143–143. 9 indexed citations

Sheldon, Helen, Wei Zhang, Esther Bridges, et al.. (2022). ELTD1 is present in extracellular vesicles derived from endothelial cells as a cleaved extracellular domain which induces in vivo angiogenesis. SHILAP Revista de lepidopterología. 1(8). e52–e52. 4 indexed citations

Sheldon, Helen, et al.. (2022). Single cell RNA‐sequencing: A powerful yet still challenging technology to study cellular heterogeneity. BioEssays. 44(11). e2200084–e2200084. 33 indexed citations

Schilling, Kathrin, Adrian L. Harris, Alex N. Halliday, et al.. (2022). Investigations on Zinc Isotope Fractionation in Breast Cancer Tissue Using in vitro Cell Culture Uptake-Efflux Experiments. Frontiers in Medicine. 8. 746532–746532. 11 indexed citations

Sheldon, Helen, Esther Bridges, Ildefonso Silva, et al.. (2021). ADGRL4/ELTD1 Expression in Breast Cancer Cells Induces Vascular Normalization and Immune Suppression. Molecular Cancer Research. 19(11). 1957–1969. 7 indexed citations

Liebscher, Ines, et al.. (2021). Elevated expression of the adhesion GPCR ADGRL4/ELTD1 promotes endothelial sprouting angiogenesis without activating canonical GPCR signalling. Scientific Reports. 11(1). 8870–8870. 16 indexed citations

Bridges, Esther, Helen Sheldon, Evelyn Ramberger, et al.. (2020). RHOQ is induced by DLL4 and regulates angiogenesis by determining the intracellular route of the Notch intracellular domain. Angiogenesis. 23(3). 493–513. 18 indexed citations

Morotti, Matteo, Esther Bridges, Alessandro Valli, et al.. (2019). Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer. Proceedings of the National Academy of Sciences. 116(25). 12452–12461. 105 indexed citations

Sheldon, Helen, Massimo Masiero, Demin Li, et al.. (2017). Abstract 777: ELTD1/ADGRL4, a novel adhesion GPCR regulator of tumour angiogenesis, suppresses lipid metabolism in endothelial cells, and is upregulated in breast cancer endothelium and epithelium. Cancer Research. 77(13_Supplement). 777–777. 2 indexed citations

10.

Harjes, Ulrike, Esther Bridges, Kshipra M. Gharpure, et al.. (2016). Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4. Oncogene. 36(7). 912–921. 58 indexed citations

11.

Roxanis, Ioannis, Helen Sheldon, Francesca M. Buffa, et al.. (2015). Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer. Oncotarget. 6(8). 5678–5694. 31 indexed citations

12.

Sheldon, Helen, et al.. (2015). Metronomic vinorelbine: Anti-angiogenic activity in vitro in normoxic and severe hypoxic conditions, and severe hypoxia-induced resistance to its anti-proliferative effect with reversal by Akt inhibition. International Journal of Oncology. 47(2). 455–464. 29 indexed citations

13.

Buffa, Francesca M., Carlos Camps, Laura Winchester, et al.. (2011). microRNA-Associated Progression Pathways and Potential Therapeutic Targets Identified by Integrated mRNA and microRNA Expression Profiling in Breast Cancer. Cancer Research. 71(17). 5635–5645. 251 indexed citations

14.

Li, Jiliang, Richard C.A. Sainson, Chern Ein Oon, et al.. (2011). DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy In Vivo. Cancer Research. 71(18). 6073–6083. 187 indexed citations

15.

Mura, Mauro Dalla, R Swain, Xiaodong Zhuang, et al.. (2011). Identification and angiogenic role of the novel tumor endothelial marker CLEC14A. Oncogene. 31(3). 293–305. 86 indexed citations

16.

Gee, Harriet E., Francesca M. Buffa, Carlos Camps, et al.. (2011). The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. British Journal of Cancer. 104(7). 1168–1177. 238 indexed citations

17.

Christlieb, Martin, et al.. (2010). Development of a new bimodal imaging methodology: a combination of fluorescence microscopy and high‐resolution secondary ion mass spectrometry. Journal of Microscopy. 240(1). 21–31. 23 indexed citations

18.

Oon, Chern Ein, Richard C.A. Sainson, Helen Sheldon, et al.. (2010). 360 Role of DLL4 and JAG1 in tumour angiogenesis. European Journal of Cancer Supplements. 8(5). 92–92. 1 indexed citations

19.

Koukourakis, Michael I., Alexandra Giatromanolaki, Helen Sheldon, et al.. (2009). Phase I/II Trial of Bevacizumab and Radiotherapy for Locally Advanced Inoperable Colorectal Cancer: Vasculature-Independent Radiosensitizing Effect of Bevacizumab. Clinical Cancer Research. 15(22). 7069–7076. 46 indexed citations

20.

Camps, Carme, Francesca M. Buffa, Stefano Colella, et al.. (2008). hsa-miR-210 Is Induced by Hypoxia and Is an Independent Prognostic Factor in Breast Cancer. Clinical Cancer Research. 14(5). 1340–1348. 540 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact